MARKET

CBIO

CBIO

Catalyst Bio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

5.28
+0.07
+1.34%
Opening 14:06 11/19 EST
OPEN
5.28
PREV CLOSE
5.21
HIGH
5.42
LOW
5.21
VOLUME
55.36K
TURNOVER
--
52 WEEK HIGH
11.29
52 WEEK LOW
4.520
MARKET CAP
63.58M
P/E (TTM)
-1.2072
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of CBIO and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

CBIO News

  • Retailers, Dubai Airshow And Cybertrucks (Stocks To Watch Podcast)
  • Seeking Alpha - Article.2d ago
  • Catalyst Biosciences to Present at the Stifel Healthcare Conference
  • GlobeNewswire.11/12 13:00
  • Catalyst Biosciences EPS misses by $0.02
  • seekingalpha.11/07 18:14
  • Catalyst Biosciences Q3 EPS $(1.06) Down From $(0.64) YoY
  • Benzinga.11/07 14:39

More

Industry

Biotechnology & Medical Research
+2.05%
Pharmaceuticals & Medical Research
+0.70%

Hot Stocks

Name
Price
%Change

About CBIO

Catalyst Biosciences, Inc., formerly Targacept, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on creating and developing medicines to address serious medical conditions. The Company focuses its product development efforts in the fields of hemostasis, including the treatment of hemophilia and surgical bleeding, and inflammation, including prevention of delayed graft function (DGF) in renal transplants and the treatment of dry age-related macular degeneration (dry AMD), a condition that can cause visual impairment or blindness. The Company's advanced program is a coagulation Factor VIIa variant, CB 813d, that has completed a Phase I clinical trial in severe hemophilia A and B patients. In addition to its lead Factor VIIa program, it has approximately two other coagulation factors, a Factor IX variant, CB 2679d/ISU 304, that is in advanced preclinical development, and a Factor Xa variant that has reached the advanced lead preclinical-stage of development.
More

Webull offers Catalyst Biosciences Inc (CBIO) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.